These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12710345)

  • 1. New therapy for "black fever" is 95% effective: India licenses the first oral drug for visceral leishmaniasis, a lethal disease of poverty.
    Indian J Med Sci; 2002 Sep; 56(9):454-6. PubMed ID: 12710345
    [No Abstract]   [Full Text] [Related]  

  • 2. New therapy for visceral leishmaniasis.
    Wkly Epidemiol Rec; 2002 Jun; 77(25):210-2. PubMed ID: 12132132
    [No Abstract]   [Full Text] [Related]  

  • 3. An oral drug for leishmaniasis.
    Jacobs S
    N Engl J Med; 2002 Nov; 347(22):1737-8. PubMed ID: 12456848
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 6. Availability of miltefosine for the treatment of kala-azar in India.
    Sundar S; Murray HW
    Bull World Health Organ; 2005 May; 83(5):394-5. PubMed ID: 15976883
    [No Abstract]   [Full Text] [Related]  

  • 7. Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction.
    Kumar N; Pandey K; Das VN; Sinha PK; Topno RK; Verma N; Lal CS; Das P; Bhattacharya SK
    Ann Trop Med Parasitol; 2007 Oct; 101(7):649-51. PubMed ID: 17877883
    [No Abstract]   [Full Text] [Related]  

  • 8. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough in the management of visceral leishmaniasis.
    Thakur BB
    J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
    [No Abstract]   [Full Text] [Related]  

  • 10. Miltefosine for visceral leishmaniasis.
    Sherwood JA
    N Engl J Med; 2000 Mar; 342(12):895. PubMed ID: 10733377
    [No Abstract]   [Full Text] [Related]  

  • 11. Miltefosine presents new hope for leishmaniasis patients.
    Paterson R
    Lancet Infect Dis; 2002 Aug; 2(8):452. PubMed ID: 12150830
    [No Abstract]   [Full Text] [Related]  

  • 12. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.
    Fischer C; Voss A; Engel J
    Med Microbiol Immunol; 2001 Nov; 190(1-2):85-7. PubMed ID: 11770118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    Herwaldt BL
    N Engl J Med; 1999 Dec; 341(24):1840-2. PubMed ID: 10588972
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination therapy for visceral leishmaniasis.
    van Griensven J; Boelaert M
    Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
    [No Abstract]   [Full Text] [Related]  

  • 15. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India.
    Thakur CP; Sinha PK; Singh RK; Hassan SM; Narain S
    Trans R Soc Trop Med Hyg; 2000; 94(6):696-7. PubMed ID: 11198660
    [No Abstract]   [Full Text] [Related]  

  • 16. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
    Sundar S; Singh A
    Expert Rev Anti Infect Ther; 2013 Feb; 11(2):117-9. PubMed ID: 23409817
    [No Abstract]   [Full Text] [Related]  

  • 17. Miltefosine (Impavido) for leishmaniasis.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):89-90. PubMed ID: 25211304
    [No Abstract]   [Full Text] [Related]  

  • 18. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kala-azar--progress against a neglected disease.
    Murray HW
    N Engl J Med; 2002 Nov; 347(22):1793-4. PubMed ID: 12456856
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.